India’s COVAXIN Vaccine Effective Against UK Variant of COVID-19

Researchers from India performed a plaque reduction neutralization test (PRNT50) using sera collected from the 26 recipients of BBV152/COVAXIN™ against hCoV-19/India/20203522 (UK-variant) and hCoV27 19/India/2020Q111 (heterologous strain). Comparable neutralization activity of the vaccinated individual’s sera showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralization escape.

Their study concluded sera from the vaccine recipients could neutralize the UK-variant strains discounting the uncertainty around potential escape. It was reassuring from the PRNT50 data generated in their laboratory that the indigenous BBV152/ COVAXIN™, following its rollout in the vaccination program, could be expected to work against the new UK-variant. It is unlikely that the mutation 501Y would be able to dampen the potential benefits of the vaccine in concern.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref link: https://doi.org/10.1101/2021.01.26.426986

#Featured